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Purpose
The purpose of this study was to compare the treatment outcomes of definitive radiotherapy
(RT) with cordectomy in patients with early glottic cancer.
Materials and Methods
A total of 165 patients who were diagnosed with T1/2 squamous cell carcinoma of the glottic
larynx between January 2006 and December 2012 were retrospectively analyzed. A total of
112 patients received RT and 53 patients received cordectomy. Local control (LC), disease-
free survival (DFS), overall survival (OS), and larynx preservation rates after RT and cordec-
tomy were investigated.
Results
The median follow-up period was 77.7 months (range, 10.7 to 127.0 months). The 3- and
5-year LC rates were 91.9% and 89.9%, respectively, for the RT group, and 82.8% and
73.2%, respectively, for the cordectomy group (p=0.006). The 3- and 5-year DFS rates were
87.5% and 83.7%, respectively, for the RT group and 79.2% and 68.0%, respectively, for
the cordectomy group (p=0.046). No significant differences were identified in the 5-year
OS (92.8% vs. 90.6%, p=0.713) or larynx preservation rates (98.2% vs. 97.2%, p=0.831)
between groups. The major failure pattern was local failure (n=26), followed by regional
(n=3) and distant failure (n=2). Multivariate analysis of LC showed that T2 stage (p=0.012)
and receiving cordectomy as initial treatment (p=0.001) were significantly associated with
poorer LC.
Conclusion
RT resulted in higher rates of LC and DFS compared to cordectomy for early glottic cancer.
Treatment with radiotherapy is feasible and should be encouraged for both T1 and T2 glottic
cancer.
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Introduction
Laryngeal cancer is one of the most common head and
neck malignancies. It is estimated that approximately 13,560
new laryngeal cancer cases occurred in the United States in
2015, accounting for 3,640 deaths [1]. Among laryngeal can-
cers, the glottic larynx is the most common subsite, being 
involved approximately three times more often than the
supraglottic larynx. Since glottic cancer involves the vocal
cord, it is often diagnosed in the early stages owing to symp-
toms such as hoarseness. In early glottic cancer, lymph node
metastasis is rare, with an incidence of clinically positive
lymph nodes of nearly zero for T1 stage and < 2% for T2
stage, and a complete cure can often be achieved [2-4]. There-
fore, the goal is to achieve the best local control (LC) leading
to a complete cure and optimal functional results.
At present, there are various treatment modalities for treat-
ing early glottic cancer; namely, radiotherapy (RT), cordec-
tomy, and surgery (e.g., partial laryngectomy). Although
│ http://www.e-crt.org │156 Copyright ⓒ 2018 by  the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
VOLUME 50 NUMBER 1 JANUARY 2018  157
surgery has been used for decades in the past, its use has
greatly decreased in recent years because of decreasing func-
tional results and advances in RT and cordectomy [5]. 
The optimal treatment for early glottic cancer has continu-
ously been an issue of debate, primarily because of the 
absence of results from large prospective randomized trials
[6]. Recent studies have shown similar LC between RT and
cordectomy. Mendenhall et al. [7] compared various nonran-
domized data and reported LC rates ranging from approxi-
mately 80% to 94% for T1 tumors and 70% to 85% for T2
tumors for both modalities [8]. In such circumstances, deci-
sions regarding the management of early glottic cancer vary
across institutions and countries [9,10]. Since there are no 
ongoing randomized trials or expected randomized trials in
the near future, it is important to review and compare retro-
spective studies. In our institution, all patients visited the 
Department of Otorhinolaryngology (ENT) first, and those
who were determined to be not adequately resectable via
cordectomy by ENT surgeons were referred to the Depart-
ment of Radiation Oncology.
This study was conducted to evaluate LC, disease-free sur-
vival (DFS), overall survival (OS), and larynx preservation
rates after RT or cordectomy as treatment options for early
glottic cancer.
Materials and Methods
1. Patients
We retrospectively reviewed the medical records of 
patients who were diagnosed with early stage squamous cell
carcinoma of the glottic larynx between January 2006 and 
December 2012 in two major clinical institutes. Early stage
glottic cancer was defined as stage Tis (in situ), T1-2 without
nodal metastases. Patients diagnosed with double primary
cancer (n=35), and patients who received treatment prior to
RT or cordectomy (n=194) or received both treatments (n=39)
were excluded. The remaining 165 patients were retrospec-
tively analyzed.
All patients were diagnosed by laryngeal microsurgery
biopsy and clinically staged according to the American Joint
Committee on Cancer seventh edition cancer staging. 
2. Treatment
Patients who were considered not adequately resectable
by cordectomy were referred for RT. Of the 165 patients, a
total of 112 received definitive RT. The median dose for 
definitive RT was 65.25 Gy (range, 58.5 to 69.75 Gy). The
most commonly used dose scheme was 64 Gy in 32 fractions
for T1 stage and 66 Gy in 33 fractions for T2 stage glottic can-
cer patients. The fractional dose was 2 Gy (n=54), 2.25 Gy
(n=56), or other (n=2). Two patients grouped as other 
received ipsilateral vocal cord irradiation with a fractional
dose of 1.8 Gy or 2.3 Gy via tomotherapy. Definitive RT was
performed by conformal RT (n=105) or tomotherapy (n=7).
The gross tumor was delineated as gross tumor volume
(GTV). The clinical target volume (CTV) was delineated 
including the whole larynx. Planning target volume (PTV)
was defined as the CTV plus an adequate margin to encom-
pass the possible setting uncertainties. For patients who 
received conformal RT, a traditional method was used;
namely, a box field with the superior border at the top of the
thyroid cartilage, the inferior border at the bottom of the
cricoid cartilage (for T2, one tracheal ring below the cricoid
cartilage), the anterior border at a 1 cm skin flash anteriorly,
and the posterior border at the anterior edge of the vertebral
body. No cone down was performed in 22 patients, and the
RT field was reduced to the ipsilateral vocal cord in 20 
patients. For the other 63 patients, the box field size was 
reduced by 1 to 2 cm depending on the patient. The median
cone down dose was 46 Gy (range, 36 to 54 Gy). For those
who received tomotherapy, but not ipsilateral vocal cord 
irradiation, the initial field was the delineated PTV, after
which cone down was performed to GTV plus margin after
56 Gy. 
A total of 53 patients received cordectomy, which was per-
formed by one of two modalities: transoral laser excision
(n=44) or transoral robotic surgery (n=9). Cordectomy types
were type I (subepithelial cordectomy, n=9), type II (subliga-
mental cordectomy, n=10), type III (transmulscular cordec-
tomy, n=5), type IV (total cordectomy, n=1), type V (exten-
ded cordectomy, n=1), and unknown (n=27). The type of
cordectomy was determined by the physician. No patients
received chemotherapy during or after treatment in either
the RT or the cordectomy group.
3. Outcome evaluation 
Follow-up was performed regularly in both the Depart-
ments of ENT and Radiation Oncology on an outpatient
clinic basis. The follow-up schedule was 1 month after com-
pletion of treatment and every 3 months for the first year,
every 6 months for 5 years, and then annually thereafter.
Events of recurrence, metastasis, and toxicity were recorded
during follow-up visits. All outpatient clinic reports were ret-
rospectively reviewed in detail to identify any toxicity
events.
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4. Statistical analysis
The primary endpoint was LC, and secondary endpoints
included DFS, OS, and larynx preservation rates. Larynx
preservation was defined as preservation of the larynx with-
out undergoing total laryngectomy. Laryngectomy types for
larynx preservation such as supracricoid laryngectomy or
vertical partial laryngectomy were not considered failures of
larynx preservation. The cumulative probability of LC, DFS,
OS, and larynx preservation rates were calculated by the 
Kaplan-Meier method and compared by the log-rank test.
Univariate and multivariate analyses of LC were performed
using Cox regression. Multivariate analysis was performed
using a backward elimination approach including all of the
variables.
Results
1. Patients and tumor characteristics
Patient and tumor characteristics are shown in Table 1. The
median age was the same for both groups, and patient char-
acteristics such as age, sex, tumor type, histologic grade, ante-
rior commissure involvement, location, and smoking history
were well balanced between groups (all p > 0.05). There was
a significant difference between the definitive RT and cordec-
tomy group in T stage (p=0.001). In the RT group, 90 patients
(80.4%) had T1/is and 22 patients (19.6%) had T2 stage dis-
ease. However, all 53 patients (100.0%) in the cordectomy
group had T1/is. There were three stage Tis patients in the RT
group and eight in the cordectomy group. Tumor type also
differed significantly between groups (p=0.022). While the
dominant tumor type in the RT group was the exophytic type,
Table 1. Patient and tumor characteristics
Characteristic Total Definitive RT Cordectomy p-value(n=165) (n=112) (n=53)
Age, median (range, yr) 63 (37-87) 64 (37-87) 64 (39-83) 0.260
Sex
Male 152 (92.1) 104 (92.9) 48 (90.6) 0.610
Female 13 (7.9) 8 (7.1) 5 (9.4)
Clinical T stage
T1/is 143 (86.7) 90 (80.4) 53 (100) 0.001
T2 22 (13.3) 22 (19.6) 0 (
Tumor type
Superficial 54 (32.7) 30 (26.8) 24 (45.3) 0.022
Exophytic 89 (53.9) 69 (61.6) 20 (37.7)
Ulcerative 15 (9.1) 10 (8.9) 5 (9.4)
Unknown 7 (4.2) 3 (2.7) 4 (7.5)
Histologic grade
NOS 46 (27.9) 27 (24.1) 19 (35.8) 0.253
Well 69 (41.8) 48 (42.9) 21 (39.6)
Moderate 46 (27.9) 33 (29.5) 13 (24.5)
Poor 4 (2.4) 4 (3.6) 0 (
AC involvement
Not involved 112 (67.9) 74 (66.1) 38 (71.7) 0.639
Involved 52 (31.5) 37 (33.0) 15 (28.3)
Unknown 1 (0.6) 1 (0.6) 0 (
Location
Both/AC involvement 55 (33.3) 41 (36.6) 14 (26.4) 0.195
Unilateral 110 (66.7) 71 (63.4) 39 (73.6)
Smoking history
Yes 107 (64.8) 72 (64.3) 35 (66.0) 0.826
No 58 (35.2) 40 (35.7) 18 (34.0)
Values are presented as number (%). RT, radiotherapy; is, in situ; NOS, not otherwise specified; AC, anterior commissure. 
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the dominant type in the cordectomy group was the superfi-
cial type. For the cordectomy group, a total of 26 out of 53
cordectomy cases reported the status of resection margin as
positive or negative, and most did not report the length of the
safety margin.
2. Local control
The median follow up period was 77.7 months (range, 10.7
to 127.0 months). LC was the primary endpoint. The 3- and 
5-year LC rates were 91.9% and 89.9% for the RT group and
82.8% and 73.2% for the cordectomy group, respectively
(p=0.006) (Fig. 1A). Since no T2 patients received cordectomy,
a subgroup analysis of only T1 glottic cancer patients was con-
Fig. 1. Kaplan-Meier estimates of local control for T1 and T2 glottic cancer (A) and Kaplan-Meier estimates of local control
for T1 glottic cancer (B). RT, radiotherapy.
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Univariate MultivariateVariable
HR 95% CI p-value HR 95% CI p-value
Age (< 65 yr:" 65 yr) 1.45 0.67-3.14 0.342 - - -
Sex (male:female) 0.94 0.22-3.99 0.936 - - -
T stage (T1/is:T2) 2.05 0.82-5.11 0.123 5.36 1.44-19.99 0.012
Tumor type (superficial:exophytic/ulcerative) 1.60 0.63-4.03 0.320 3.39 0.95-12.13 0.061
Histologic grade (WD:MD/PD) 0.88 0.36-2.14 0.769 - - -
AC involvement (no:yes) 1.67 0.77-3.64 0.197 - - -
Location (both/AC involvement:unilateral) 0.66 0.30-1.43 0.288 - - -
Smoking history (no:yes) 1.27 0.55-2.91 0.580 - - -
Treatment (radiotherapy:cordectomy) 2.83 1.31-6.14 0.008 7.79 2.35-25.87 0.001
Table 2. Multivariate Cox regression model for local recurrence
HR, hazard ratio; CI, confidence interval; is, in situ; WD, well differentiated; MD, moderately differentiated; PD, poorly differ-
entiated; AC, anterior commissure.
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ducted. For T1 patients (n=143), the 3- and 5-year LC rates
were 95.6% and 93.0%, respectively, for the RT group (n=90),
and 82.8% and 73.2% for the cordectomy group (n=53)
(p=0.001) (Fig. 1B). Multivariate analysis revealed that LC was
adversely affected by a T stage of T2 (hazard ratio [HR], 5.36;
95% confidence interval [CI], 1.44 to 19.99; p=0.012) and
cordectomy as a treatment modality (HR, 7.79; 95% CI, 2.35 to
25.87; p=0.001) (Table 2).
3. Survival
The 3- and 5-year DFS rates were 87.5% and 83.7%, respec-
tively, for the RT group and 79.2% and 68.0%, respectively, for
the cordectomy group (p=0.046) (Fig. 2). A subgroup analysis
of T1 glottic cancer patients showed similar results with 3- and
5-year DFS rates of 91.9% and 87.0%, respectively, for the RT
group and 75.5% and 64.8%, respectively, for the cordectomy
group (p=0.007). For OS, no significant differences were iden-
tified between the 3- and 5-year OS. The 3- and 5-year OS rates
were 94.6% and 92.8%, respectively, for the RT group and
94.3% and 90.6%, respectively, for the cordectomy group
(p=0.713) (Fig. 3).
Two patients in the RT group and one in the cordectomy
group died of disease progression. Other causes of death were
a newly developed second malignancy (n=8), postoperative
bleeding after salvage surgery (n=1), aspiration pneumonia
(n=1), and unknown because of follow-up loss with no evi-
dence of disease (NED) status (n=11). The newly developed
second malignancies were hepatocellular carcinoma, cholan-
giocarcinoma, pancreatic cancer, esophageal cancer, and lung
cancer. 
4. Patterns of failure and larynx preservation
In the definitive RT group, a total of 12 local failures, three
regional failures, and one distant failure occurred. All failures
occurred independently. For local failures, failure sites 
included the involved vocal cord. For patients with recurrent
stage T1 or T2N0M0, salvage treatment modalities were
cordectomy (n=4), re-irradiation (n=1), supracricoid partial 
laryngectomy (n=1), and none because of a second primary
cancer (n=1). Among four patients who received salvage
cordectomy, two were salvaged successfully, one died of lung
cancer, and one died due to disease progression. For recurrent
stage T3 or T4N0M0, salvage treatment modalities were total
laryngectomy (n=3), supracricoid partial laryngectomy (n=1),
and none because of follow-up loss (n=1). Among regional
failures, two were treated with salvage neck dissection fol-
lowed by postoperative RT and one was treated with salvage
chemoradiotherapy. One distant failure that occurred in the
T-spine was successfully salvaged by RT.
In the cordectomy group, a total of 14 local failures and one
distant failure occurred. Almost all local failure sites included
the ipsilateral vocal cord, except for one failure that occurred
in the contralateral vocal cord. One distant failure occurred as
a hilar lymph node metastasis and was treated with RT. Sal-
vage treatment modalities performed for local recurrences
were laryngeal microsurgery (n=2), vertical partial laryngec-
Fig. 2. Kaplan-Meier estimates of disease-free survival.
RT, radiotherapy.
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Fig. 3. Kaplan-Meier estimates of overall survival. RT, 
radiotherapy.
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tomy or supracricoid partial laryngectomy (n=3), cordectomy
(n=3), RT (n=5), and none because of follow-up loss (n=1). All
five patients who received salvage RT were salvaged success-
fully. 
Larynx preservation rates showed no significant difference
between the groups. For the RT group, the 3- and 5-year larynx
preservation rates were 98.2%, while they were 100.0% and
97.2% in the cordectomy group (p=0.831).
5. Complications
During RT, three patients experienced a grade III skin reac-
tion and two experienced grade III pharyngitis. Additionally,
one patient required a 1-week break during treatment because
of a grade III skin reaction. There were no late complications
more severe than grade 2. When follow-up of the patients in
the RT group was conducted in the radiation oncology depart-
ment, subjective scoring of the voice quality was performed.
The patient scored the voice quality in a scale of 0 to 100. The
score for most patients was more than 80, but six patients
(5.4%) still complained of continued hoarseness at a median
of 10 months (range, 3 to 44 months) after treatment. In the
cordectomy group, in one institution, patients who com-
plained of severe voice impairment underwent assessment
that included speech intelligibility and the percentage of con-
sonants correct as criteria, which resulted in three patients
being diagnosed with phonation disorder. In the other insti-
tution, voice handicap index was assessed for two-thirds of
the patients who received cordectomy, and a total of six 
patients (11.3%) complained of moderate to severe voice 
impairment at a median of 13 months (range, 2 to 46 months)
after cordectomy. 
Discussion
In our study, the RT group had better LC and DFS than the
cordectomy group, with a 5-year LC rate of 89.9% and 73.2%,
and a DFS rate of 83.7% and 68.0%, respectively. In addition,
multivariate analysis revealed that LC was adversely 
affected by T stage and cordectomy as the first treatment
choice. Currently, there are variable results regarding what
the optimal treatment modality for early glottic cancer is, and
to the best of our knowledge, this is the first study to show
favorable results for RT.
In comparison to our results, previous studies have shown
different results concerning LC. O’Hara et al. [11] conducted
a review of 36 publications and concluded that there was no
demonstrable difference in LC between RT and transoral
laser surgery. The 3-year LC rates were 89.3% and 88.9% for
RT and transoral laser surgery, respectively, for stage IA 
tumors and 86.2% and 76.8%, respectively, for stage IB 
tumors [11]. Another comprehensive systemic review by Yoo
et al. [6] also concluded that there is no evidence in favor of
either treatment. 
An Italian study of RT alone showed 3-year and 5-year LC
rates of 86% and 84%, respectively, for 831 T1 glottic cancer
cases. For 256 T2 glottic cancer patients, the 3-year and 5-year
LC rates were both 73% [12,13]. In our study, the results were
superior for T1 stage, with 3-year and 5-year LC rates of
95.6% and 93%, respectively, and 3-year and 5-year LC rates
of 77.0% for both for stage T2. For cordectomy, Canis et al.
[14] reported a 5-year LC rate of 86.8% for 404 patients with
T1a glottic cancer who received transoral laser microsurgery.
The results were inferior in our analysis, with a 5-year LC
rate of 73.2% for T1 patients. Therefore, the favorable results
for RT group in our study may have been due to the superior
results of the RT group and the inferior results of the cordec-
tomy group compared to previous reports. 
In our study, the RT field was uniformly set for nearly all
patients. The RT field generally not only included the gross
tumor area but also areas concerned with microscopic 
extension. Cordectomy, on the other hand, has anatomical
limitations that makes it difficult to expose the tumor ade-
quately, especially with thyroid cartilage, cricothyroid mem-
brane, and para-arytenoid musculature acting as limitations
[15]. In addition, the extent of resection is always a dilemma
for surgeons since resection extent is closely linked with
voice quality [16]. Thus, cordectomy may not have been suf-
ficient to control the local disease in some cases. While the
results of cordectomy may vary across surgeons and institu-
tions, when we examined whether there were any differences
in LC between surgeons and the year in which cordectomy
was performed, neither were found to differ significantly. 
Although LC differed significantly between the RT and
cordectomy groups, OS did not show any significant differ-
ences, which is consistent with the results of other studies
[6]. A total of 26 local failures, three regional failures, and one
distant failure occurred, but only three patients died of dis-
ease progression, demonstrating that recurrent glottic cancer
could be salvaged in most cases in both treatment groups. 
As for laryngeal preservation, there are various results 
reporting that there are no differences between the two treat-
ments, or that the likelihood of laryngeal preservation may
be higher with cordectomy [6-8]. Our results showed high
rates of 5-year larynx preservation in both groups that did
not differ significantly, with 98.2% and 97.2% being observed
for the RT and cordectomy groups, respectively. 
Since disease control rates of early glottic cancer are good
with both treatment modalities, quality of voice is an essen-
tial concern. Aaltonen et al. [17] reported the first random-
ized study concerning voice quality of early laryngeal cancer
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patients. Patients who received RT or transoral laser surgery
had similar overall voice quality, but RT resulted in a less
breathy voice [17]. Others reported that voice quality was
better in the RT group [18,19]. In our study, although there
were limitations for the assessment of voice quality, there
were more patients with severe voice impairments in the
cordectomy group.
An interesting exception in the RT group was the two 
patients who received ipsilateral cord irradiation via tomo-
therapy, which is a modality attracting increasing interest
with favorable results for both tumor control and promising
voice quality [16]. These two patients have been followed up
until now with NED status at 89.1 and 70.4 months, respec-
tively. In addition, the fact that almost all local recurrences
occurred at the ipsilateral vocal cord supports the possibility
of treating only the ipsilateral vocal cord.
There are several limitations to our study, including its ret-
rospective nature. In addition, objective voice quality assess-
ment was not performed for all patients during follow-up.
Thus, it is challenging to determine if one treatment modality
is superior to another with respect to voice quality, which is
an important factor in the decision about early glottic cancer
treatment. Furthermore, the resection margins of specimens
from cordectomy were not reported in many cases, making
it difficult to confirm the cause of the lower LC in the cordec-
tomy group.
However, to the best of our knowledge, this is the first
study to demonstrate favorable results of RT over cordec-
tomy. Currently, there are no prospective randomized trials
and none are expected in the future; thus, decisions must be
based on nonrandomized data. Most previous data show
similar control rates of early glottic cancer for RT and cordec-
tomy, and in some, a lower control rate for RT [6,11,20]. Since
cordectomy outcomes can be influenced by many factors, 
including those associated with the location and surgeon, 
results may vary among studies. 
In contrast to cordectomy, the favorable results of RT can
be explained by unvarying inclusion of the tumor area in the
RT field. Moreover, patients in the RT group did not experi-
ence any severe acute or late complications, and all but six
patients (5.4%) recovered voice quality. Thus, it seems rea-
sonable that RT should be encouraged in both T1 and T2 glot-
tic cancer, while cordectomy should be encouraged in
adequately excisable cases of early glottic cancer.
RT resulted in higher rates of LC and DFS compared to
cordectomy for early glottic cancer (T1/2), with low compli-
cation rates and acceptable voice quality. Treatment with 
radiotherapy is feasible and should be encouraged for both
T1 and T2 glottic cancer.
Conflicts of Interest
Conflict of interest relevant to this article was not reported.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Can-
cer J Clin. 2015;65:5-29.
2. Ries LA, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer
EJ, et al. SEER cancer statistics review, 1975-2003. Bethesda,
MD: National Cancer Institute; 2006.
3. Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. 
T1-T2N0 squamous cell carcinoma of the glottic larynx treated
with radiation therapy. J Clin Oncol. 2001;19:4029-36.
4. Karatzanis AD, Psychogios G, Zenk J, Waldfahrer F, Hornung
J, Velegrakis GA, et al. Comparison among different available
surgical approaches in T1 glottic cancer. Laryngoscope. 2009;
119:1704-8.
5. Silver CE, Beitler JJ, Shaha AR, Rinaldo A, Ferlito A. Current
trends in initial management of laryngeal cancer: the declining
use of open surgery. Eur Arch Otorhinolaryngol. 2009;266:
1333-52.
6. Yoo J, Lacchetti C, Hammond JA, Gilbert RW; Head and Neck
Cancer Disease Site Group. Role of endolaryngeal surgery
(with or without laser) versus radiotherapy in the manage-
ment of early (T1) glottic cancer: a systematic review. Head
Neck. 2014;36:1807-19.
7. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Vil-
laret DB. Management of T1-T2 glottic carcinomas. Cancer.
2004;100:1786-92.
8. Abdurehim Y, Hua Z, Yasin Y, Xukurhan A, Imam I, Yuqin F.
Transoral laser surgery versus radiotherapy: systematic 
review and meta-analysis for treatment options of T1a glottic
cancer. Head Neck. 2012;34:23-33.
9. Makki FM, Williams B, Rajaraman M, Hart RD, Trites J, Brown
T, et al. Current practice patterns in the management of glottic
cancer in Canada: results of a national survey. J Otolaryngol
Head Neck Surg. 2011;40:205-10.
10. O'Sullivan B, Mackillop W, Gilbert R, Gaze M, Lundgren J,
Atkinson C, et al. Controversies in the management of laryn-
geal cancer: results of an international survey of patterns of
care. Radiother Oncol. 1994;31:23-32.
11. O’Hara J, Markey A, Homer JJ. Transoral laser surgery versus
radiotherapy for tumour stage 1a or 1b glottic squamous cell
carcinoma: systematic review of local control outcomes. J
Laryngol Otol. 2013;127:732-8.
References
Cancer Res Treat. 2018;50(1):156-163
VOLUME 50 NUMBER 1 JANUARY 2018  163
12. Frata P, Cellai E, Magrini SM, Bonetti B, Vitali E, Tonoli S, et
al. Radical radiotherapy for early glottic cancer: results in a 
series of 1087 patients from two Italian radiation oncology cen-
ters. II. The case of T2N0 disease. Int J Radiat Oncol Biol Phys.
2005;63:1387-94.
13. Cellai E, Frata P, Magrini SM, Paiar F, Barca R, Fondelli S, et
al. Radical radiotherapy for early glottic cancer: results in a 
series of 1087 patients from two Italian radiation oncology cen-
ters. I. The case of T1N0 disease. Int J Radiat Oncol Biol Phys.
2005;63:1378-86.
14. Canis M, Ihler F, Martin A, Matthias C, Steiner W. Transoral
laser microsurgery for T1a glottic cancer: review of 404 cases.
Head Neck. 2015;37:889-95.
15. Davis RK, Jako GJ, Hyams VJ, Shapshay SM. The anatomic
limitations of CO2 laser cordectomy. Laryngoscope. 1982;
92(9 Pt 1):980-4.
16. Mendelsohn AH, Xuan Y, Zhang Z. Voice outcomes following
laser cordectomy for early glottic cancer: a physical model 
investigation. Laryngoscope. 2014;124:1882-6.
17. Aaltonen LM, Rautiainen N, Sellman J, Saarilahti K, Makitie
A, Rihkanen H, et al. Voice quality after treatment of early
vocal cord cancer: a randomized trial comparing laser surgery
with radiation therapy. Int J Radiat Oncol Biol Phys. 2014;90:
255-60.
18. Arias F, Arraras JI, Asin G, Uzcanga MI, Maravi E, Chicata V,
et al. Quality of life and voice assessment in patients with
early-stage glottic cancer. Head Neck. 2015;37:340-6.
19. Laoufi S, Mirghani H, Janot F, Hartl DM. Voice quality after
treatment of T1a glottic cancer. Laryngoscope. 2014;124:1398-
401.
20. Brady JS, Marchiano E, Kam D, Baredes S, Eloy JA, Park RC.
Survival impact of initial therapy in patients with T1-T2 glottic
squamous cell carcinoma. Otolaryngol Head Neck Surg.
2016;155:257-64.
Seung Yeun Chung, Optimal Treatment of Early Glottic Cancer
